Pasithea Therapeutics Corp.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $486,559 | $15,062 |
| Cost of revenue | — | — | — | $113,195 | $17,275 |
| Gross profit | — | — | — | — | -$2,213 |
| Selling, general & administrative | — | $7.1M | $7.9M | $9.9M | $4.5M |
| Research and development | $8.0M | $7.2M | $8.1M | $2.7M | — |
| Operating income | -$20.9M | -$14.2M | -$16.0M | -$12.6M | -$4.5M |
| Interest expense | — | — | — | $102 | $508 |
| Pretax income | -$20.4M | -$13.9M | -$15.5M | -$11.7M | -$2.2M |
| Net income | -$20.4M | -$13.9M | -$16.0M | -$13.9M | -$2.2M |
| Balance Sheet | |||||
| Cash and equivalents | $55.2M | $6.9M | $16.3M | $33.1M | $53.0M |
| Current assets | $56.5M | $7.4M | $16.7M | $34.1M | $53.3M |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M |
| Current liabilities | $5.0M | $1.1M | $2.6M | $1.9M | $447,280 |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M |
| Stockholders' equity | $55.2M | $14.8M | $23.4M | $42.5M | $51.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.2M | -$13.9M | -$12.8M | -$14.6M | -$3.2M |
| Depreciation and amortization | $32,421 | $18,865 | $18,290 | $5,094 | $1,379 |
| Stock-based compensation | $297,467 | $773,693 | $592,269 | $835,064 | $471,250 |
| Capital expenditure | — | — | $34,301 | $107,101 | $21,503 |
| Free cash flow | — | — | -$12.8M | -$14.7M | -$3.2M |
| Share repurchases | — | — | $3.7M | $3.2M | — |
| Impairments | $4.2M | — | — | — | — |
Shares outstanding 33.4M · Free float 64.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.